VC Fund Dossiers

Tapiero is one of the few VCs who actually "gets" crypto infrastructure at scale — this isn't some converted Web 2.0 fund trying to catch the wave. They claim to be "the only growth equity fund in the world solely focused on crypto" and are "dictating pricing" right now, which is either confidence or arrogance depending on your perspective. Six exits in one year including Circle, Gemini, eToro IPOs and the Deribit acquisition is genuinely impressive. The rebrand to 50T and updated projection of $50 trillion ecosystem value feels very 2021-ish, but their portfolio performance suggests they're not just hot air. The fact that the two original co-founders "went their separate ways" with Stan Miroshnik starting his own fund TenSquared raises questions about internal dynamics, though both seem to have maintained their 10T positions.

1315 Capital is a solid mid-tier fund that actually knows their sectors, especially healthcare where Nikhil Krishnan brings real expertise and network. They're not going to lead your Series C, but they can be genuinely helpful at Series A/B with operational support and introductions. Chris Sugden has been-there-done-that credibility as a former operator. The fund is still relatively new (launched 2020) so track record is limited, but early portfolio companies speak positively about their involvement. They won't give you the brand name cachet of top-tier funds, but they also won't ghost you post-investment.

Here's the real deal on A91: They're the 'Sequoia mafia' done right. Founded by three former Sequoia managing partners, they actually know how to build companies, not just write checks. Their $665M third fund closed in April 2025 was one of the largest VC fundraises in India, signaling serious LP confidence. The portfolio speaks volumes - Digit Insurance is expected to go public, and they've had partial exits from Atomberg and spice maker Pushp. What founders love: these guys actually get their hands dirty post-investment and have the operational chops to help scale. What to watch: they're raising average investment sizes to $35-40M with their new fund, so they're moving upmarket and may be less accessible for smaller rounds.

ABS is the definition of a solid, unsexy regional fund that gets the job done. They're not going to win any innovation awards or get you TechCrunch headlines, but they actually know how to help B2B software companies scale profitably. Tim Weglicki will dig deep into your unit economics and hold you accountable to growth metrics - some founders love this discipline, others find it suffocating. They're particularly strong if you're in Baltimore/DC area and need someone who understands enterprise sales cycles. Don't expect them to lead hot consumer rounds or move at Silicon Valley speed, but they'll stick with you through tough times and actually know how to build sustainable businesses.

Accel-KKR is the definition of steady, operational value creation - they're not looking for moonshots, they want profitable software companies they can make more profitable. They have a reputation for being founder-friendly in growth deals but can be more controlling in buyout situations. Their operational playbook is solid and they actually deliver on promises of sales acceleration and process optimization. The downside? They're not going to get excited about your pre-revenue AI startup or unproven market category. They want to see the revenue, the margins, and a clear path to optimization.

Acorn is a solid but unremarkable regional player that does what it says on the tin - they write checks to profitable, established businesses and help them grow incrementally. They're not going to push you to swing for the fences or pivot into some crazy new market, which is either exactly what you want or incredibly frustrating depending on your ambitions. The partners are straight shooters who know their lanes and don't pretend to be Silicon Valley hotshots. If you're a steady, profitable business in the heartland looking for patient capital and operational guidance without the drama, they're probably a good fit.

AE Industrial is the real deal for defense tech, but know what you're getting into. These guys actually understand the Pentagon procurement maze and have genuine relationships that matter in this space. The partners have been on both sides of the table - buying and selling to the government - which is invaluable. However, they're private equity minded, so expect heavy operational involvement and pressure for near-term government contracts. If you're building consumer tech that might pivot to defense 'someday,' look elsewhere. But if you have real defense customers and need people who speak DOD fluently, they're worth the conversation.

Alkeon is the hedge fund that became a VC - they bring serious analytical rigor and late-stage firepower, but don't expect warm fuzzy founder support. They're numbers-driven, move fast on decisions, and have serious capital to deploy. The upside: they're not trying to be your friend, they're trying to make money, which can actually be refreshing. The downside: if your metrics slip, expect tough conversations. They're particularly strong for companies that need growth capital but don't want the typical VC hand-holding.

ACG has a proven track record with 17 exits to date and some genuine consumer brand home runs - but here's what founders need to know: they just raised a relatively modest $160M Fund V, bringing total AUM to $1B+. Josh Goldin is legitimately well-connected and has been doing this since before consumer brands were cool. Their sweet spot is $10-50M checks for companies doing $5-50M revenue, and they genuinely add value through their network. The real test is how they perform in today's tougher consumer environment - their last few years have been riding the DTC wave, but now they need to prove they can pick winners when growth is harder to come by.

Cetin only looks 3-4 years ahead for exits and won't touch early-stage - 'I am like a goldfish,' he says. They're genuinely hands-on: every team member talks to their portfolio company CEOs at least twice a month. With almost €2bn AUM and 12 unicorns in their portfolio, they've got serious firepower. But they're conservative to a fault - passed on AI hype and blockchain, waiting for 'second wave' opportunities. The real value? Direct access to Allianz's massive customer base and distribution network for strategic partnerships.

Alpha Wave is essentially the house that SpaceX built - their single largest investment gave them the credibility to play in the big leagues of AI investing. Recent 50.1% acquisition by Abu Dhabi's IHC signals they're more sovereign wealth fund satellite than pure VC now. The good news: they have serious capital and global reach. The reality check: with 31 partners across 11 offices and 274 investments, you're getting the institutional machine treatment, not boutique attention. Rick Gerson has the Rolodex and board seats, but founders report the firm can feel bureaucratic post-investment. They're betting big on AI infrastructure plays and have the AUM to write large checks, but expect slower decision-making and more process than a traditional growth fund.

This is the debt fund founders actually want to work with. Vinod and team have been in the trenches for 15+ years and genuinely understand startup cash flow dynamics - they won't panic when your metrics dip or try to control your board. The 'patient capital' reputation is real, but don't mistake that for being pushy about returns. They're disciplined about only backing companies with solid VC sponsors, which means if you get Alteria, you're probably on the right track. The trade-off? Their rates aren't cheap and they stick to their lane - don't expect them to lead equity rounds or provide strategic connections like top VCs do.

Altimeter is Brad Gerstner's show, and he's a polarizing figure who founders either love or find exhausting. He's genuinely smart and well-connected, but expect strong opinions and public commentary that might put your company in the spotlight. They write big checks and have conviction, but decision-making runs through Brad, so if he's not bought in, you're dead in the water. Portfolio companies say they're helpful post-investment with connections and strategic advice, but don't expect warm and fuzzy - this is a performance-driven shop.

Amador is a focused regional player that actually knows their market - Latin America's urban middle class. They got into quality deals like Nuvocargo's $36.5M Series B and Fracttal's $10M Series A, showing they can source and win competitive rounds. The team has solid traditional finance backgrounds but not flashy startup experience, which could be good or bad depending on what you need. Adding a Mexico partner suggests they're serious about geographic expansion. The fund size appears modest based on portfolio activity, so expect hands-on involvement but maybe not the deep pockets for major follow-ons.

Ampersand is the steady Eddie of healthcare investing - they know their lane and stick to it religiously. These guys have been doing healthcare growth deals since before it was cool and have genuine operational chops. They're not flashy or fast, but they're thorough and actually helpful post-investment. The catch? They move at healthcare industry speed (read: glacial) and their due diligence process can feel like getting a root canal. If you're a hot SaaS company looking for quick growth capital, look elsewhere. But if you're in healthcare services or HIT and want investors who actually understand your regulatory headaches and can help with acquisitions, they're solid.

Angeleno Group is the energy transition OG - they were betting on clean tech before it was cool, literally founding the firm in 2001 when 'clean energy' wasn't even in most VCs' vocabulary. The founders are a compelling duo: Weiss brings legal/policy chops from white-shoe law firm O'Melveny and actual White House experience, while Tepper has serious finance credentials (grew a fund from $150M to $2B at Aetna). Their advisory board is genuinely impressive - Janet Yellen, Ernest Moniz, Frances Arnold - these aren't vanity adds, they're heavy hitters who signal serious conviction. In more than two decades, Tepper and Weiss' firm has invested in nearly 40 companies and has led or co-led funding totaling about $3 billion. But here's what matters for founders: they're sector-focused but stage-agnostic, which means they can follow you from growth through exit. The $10-30M check size is real money that moves needles.

Apposite is that rare breed - a genuinely healthcare-obsessed fund that actually knows what it's talking about. Nearly half their LPs are committed to healthcare impact investing, and their portfolio companies have achieved 20%+ annual revenue and employment growth on average - which is solid execution, not just marketing fluff. The Ulthera exit to Merz for up to $600M shows they can deliver returns, and founders consistently praise their hands-on approach. They're small with a flat hierarchy and human touch - think boutique healthcare specialists, not spreadsheet jockeys. The downside? £5M-£20M check sizes and £200M under management means they're playing in a specific sandbox - great if you fit, limiting if you don't. They're genuinely impact-focused, which is refreshing, but also means they'll pass on profitable healthcare plays that don't move the needle on patient outcomes.

Ara Partners is one of the more pragmatic climate funds out there — they actually understand that industrial companies move slowly and care about ROI more than saving the planet. Their partners have real industrial experience, which is rare in this space where most climate VCs are ex-consultants who've never set foot in a factory. They're not chasing the latest shiny climate tech object; they focus on proven technologies that can actually scale in heavy industry. The downside? They're relatively new as a fund and their portfolio is still proving itself. If you're building something for manufacturing or heavy industry, they get the sales cycles and regulatory headaches better than most VCs.

Here's the thing about Ascent: they've actually delivered. Two unicorns (Cult.fit, ACKO), eight IPOs, and ten acquisitions in their portfolio isn't marketing fluff. Their 32 percentage points higher exit rate compared to other VCs shows they know how to get money back to LPs. Raja Kumar brings serious regulatory gravitas - former SEBI official who successfully transitioned from civil service to PE, which is rare in India. The downside? They're conservative - typically less than 2 deals per year, only 1 funding round in the last 12 months. But if you're looking for patient capital from someone who understands Indian markets deeply and has $1 billion under management, they're solid. Just don't expect them to move fast or lead every round.

Asia Partners is the real deal - a rare fund that actually knows how to operate at scale, not just write checks. Nash and Rippel have legit operator credentials (Sea IPO, Flipkart exit) that most VCs can only dream of. Their Series C/D focus is smart - they're filling the gap where founders need help transitioning from startup to scale-up, which is exactly where their operating experience shines. The catch? They've only made 9 investments with 1 new one in the last 12 months - they're extremely selective, which means getting their attention requires serious traction. Their portfolio concentration in Singapore-based companies also suggests they prefer proximity for hands-on involvement.

Atlantic Bridge is the old guard of European tech - they've been doing cross-border deals since before it was cool. Brian Long and team have serious operator credentials (multiple IPOs, actual chip company exits) which matters when you're pitching deep tech. They're not just check-writers - they genuinely help European companies crack the US market through their Palo Alto office and connections. However, note that Atlantic Bridge gradually exited their entire position in Navitas stock in 2025 despite the company's strong showing that year - they know when to take profits. Their exit track record is legitimately impressive: Movidius to Intel, DecaWave to Qorvo, Blue Data to HPE, Hedvig to Commvault, NuVia to Qualcomm. They're particularly strong in semiconductors and enterprise software, but they move slowly and do serious due diligence.

Gavin Baker is one of the most respected growth investors in the game, with a track record that speaks for itself from his Fidelity days. The guy doesn't chase fads - he finds exceptional companies and holds them through thick and thin. That said, Atreides is essentially Gavin's show, so you're betting on one person's judgment. He's incredibly thoughtful and has genuine operational insights, but the fund is still relatively new as an independent entity. If you can get him interested, he's the kind of investor who will stick with you through tough times and genuinely help you think through long-term strategy.

Avenir is the fund you call when you need serious operational help scaling from $10M to $50M ARR, not when you want strategic vision or early-stage hand-holding. They're former bankers and growth operators who actually know how to read a P&L and will push you hard on unit economics. Portfolio companies rave about their operational discipline but note they can be pretty demanding on metrics and reporting. If you're looking for patient capital or someone to validate your pivot ideas, look elsewhere. If you want someone to help you build a machine that prints money, these are your people.

Baillie Gifford is the rare VC that actually practices what they preach about long-term thinking - they held Tesla through multiple near-death experiences and SpaceX when everyone thought Elon was crazy. They're not your typical Sand Hill Road fund; they're Scottish, patient, and genuinely contrarian. The flip side? They can be painfully slow to decide and their bar is astronomically high. If you're looking for quick Series A money or need hands-on operational help, look elsewhere. But if you're building something that could reshape an industry and want investors who won't panic during rough patches, they're gold.

BCLS is the institutional life sciences money with serious firepower and a track record that speaks volumes. Their Cerevel exit to AbbVie for $8.7B delivered a 10x return on their $250M investment, and SpringWorks IPO'd in 2019 with them owning 17%. They've cracked the code on pharma carve-outs and spin-offs better than almost anyone. They just led a $300M investment in a new company built around Bristol Myers assets, following their successful playbook with Cerevel and SpringWorks. The downside? This is big money looking for big outcomes - if you're not swinging for billion-dollar exits, you're probably not their speed. They have the Bain pedigree and consulting DNA, so expect thorough due diligence and operational involvement.

BaltCap is the Baltic heavyweight you go to when you want an investor who actually knows how to build companies in emerging Europe. Portfolio CEOs rave about their decade-plus partnerships and result-oriented approach, which tells you everything about their post-investment value-add. The recent €100M+ infrastructure fund embezzlement scandal involving partner Šarūnas Stepukonis was a black eye, but their handling shows institutional maturity. They're the rare Eastern European fund that can execute London Stock Exchange take-privates and has genuine multi-decade track record. Their focus on digitization and automation shows they get where markets are heading, not just chasing yesterday's winners.

Base Partners is essentially the Brazilian bridge fund for US tech unicorns who want to crack Latin America but can't be bothered to figure it out themselves. They're backed by influential Brazilian business owners and pride themselves on helping portfolio companies capture the Brazilian market through depth and consistency. The model is simple: write late-stage checks to proven winners, then use their network of wealthy Brazilian families to open doors locally. With 12 unicorns in their portfolio including Figma and Nubank, they clearly know how to pick winners. But founders should know this isn't really venture capital in the traditional sense - you're paying for distribution and market access, not early-stage risk capital or hands-on company building.

These are the SoftBank Latin America dream team who actually got stuff done before Vision Fund went sideways. Claure brings serious operator credibility - he actually built and sold companies, not just wrote checks. The guy turned around Sprint and engineered a $195B merger, so he knows how to make shit happen. Nyatta is the investing brain with McKinsey/JPMorgan pedigree who co-built SoftBank's LATAM funds from scratch. They're not tourists - this is their home turf and they have real conviction about the region's potential. The $500M fund size is perfect for growth-stage deals without the crazy valuations that killed their former employer. But here's the thing: they're ex-SoftBank, which means they've seen what happens when you move too fast and burn too much money. That could be wisdom or it could be baggage.

Blackstone Growth is the institutional money machine you want when you're ready to scale globally and go public. They write massive checks and actually deliver on operational support through their platform, but they're not your friendly neighborhood VC. They expect private equity-level performance metrics and quarterly business reviews that make Series A founders break out in hives. The upside is real access to Fortune 500 customers, international expansion help, and a team that knows how to navigate IPO processes. The downside is they'll restructure your board, bring in their own executives, and push for aggressive growth that sometimes breaks companies that aren't truly ready for prime time.

BOND is essentially Mary Meeker's personal investment vehicle wrapped in a fund structure, which cuts both ways. On the upside, you get one of the most respected internet analysts ever and her incredible network from decades at Morgan Stanley and Kleiner Perkins. The data-driven approach is real — they'll dive deep into your metrics and actually understand your business model. Downside: they're relatively new as a fund (2019), so the jury's still out on their actual value-add beyond the check and brand name. They seem to prefer backing companies that already have strong momentum rather than taking big early bets, which makes sense for their large fund size but might not be ideal if you need true partnership in the early days.

Bregal Sagemount is the grown-up in the room for later-stage B2B companies that need serious capital and operational expertise. They write big checks ($20-100M+) and actually know how to scale enterprise software businesses, which separates them from the flashier early-stage funds. The downside? They're not going to hold your hand or get excited about your vision deck - they want to see real revenue, real customers, and a clear path to much bigger revenue. Partners are operationally savvy but can be pretty demanding on metrics and milestones. If you're a founder who wants strategic guidance more than just capital, they deliver.

Brighton Park is the definition of a steady, under-the-radar growth equity fund that does exactly what it says on the tin. They're not trying to be the next hot brand name - they just write checks to profitable B2B companies that need growth capital. The healthcare focus is real and deep, which can be incredibly valuable if that's your space. Don't expect them to help you pivot or figure out product-market fit - they invest in businesses that already have their shit together and just need fuel. The partners are competent operators but won't blow you away with visionary insights. Good for founders who want capital plus solid, if unremarkable, board members.

BII is the UK government's development arm masquerading as a venture fund, with all the bureaucracy that entails. Parliament has criticized them for being 'poorly targeted' on poverty reduction and focusing too much on middle-income countries rather than the most marginalised groups. There's a growing mismatch between BII's ambitious climate and mobilization goals and their entirely shareholder equity-funded balance sheet. Critics question whether their India investments are actually 'additional' to what private investors would do anyway. The new CEO Leslie Maasdorp talks a big game about mobilizing private capital, but BII moves at government speed with development impact frameworks that would make a McKinsey consultant weep. If you want patient capital and can stomach the ESG reporting requirements, they're solid. But don't expect VC-style decision making or risk appetite.

Here's the real talk: I can't find any credible information about Capital Today as a Singapore-based VC fund. Their website doesn't provide useful content, and they don't appear in any major VC databases or industry lists for Singapore. This could mean they're either extremely stealth, very new, or potentially not an active fund. Before taking any meeting, founders should verify this fund actually exists and has real capital to deploy - ask for recent portfolio examples, fund size, and partner backgrounds.

CapitalG is Alphabet's growth equity arm, which means they come with the ultimate strategic asset: Google's platform, data, and distribution. The good news is they're genuinely founder-friendly and don't push Google partnerships - they let value emerge naturally. Partners like David Lawee have serious operator credibility and the fund moves fast on decisions. The potential downside? Taking Google money can create competitive dynamics with other tech giants, and some founders worry about information sharing (though CapitalG maintains strict walls). They're particularly strong for companies that can benefit from Google Cloud, search traffic, or Android/Play Store distribution.

Capricorn is one of the OG climate tech funds that survived the cleantech 1.0 crash and learned hard lessons about market timing and technology readiness. They're legitimately thesis-driven rather than just trend-chasing, but this means they can be slow to move on deals outside their wheelhouse. Their partners have real operational experience and corporate connections that matter for B2B climate companies. The downside is they can be overly conservative on valuations and sometimes miss fast-moving opportunities while they're doing extensive diligence on market dynamics.

Catalyst is a solid, no-frills B2B shop that actually knows how to pick winners - their portfolio speaks for itself. Brad and Rick are former operators who get in the weeds and genuinely help with product and go-to-market strategy, not just intro-making VCs. They're not flashy or prolific on social media, which some founders love because it means they're focused on the work. The downside? They can be pretty selective and their process can feel slow if you're used to faster-moving funds. They also tend to have strong opinions about business models and won't hesitate to tell you if they think your approach is wrong.

CDPQ brings serious capital and patient money, but you're dealing with a pension fund, not a traditional VC shop. The upside: they write big checks, don't need quick exits, and have deep pockets for follow-ons. The reality check: decision-making can be glacial, they're risk-averse by nature, and you'll navigate more bureaucracy than a typical fund. They're excellent for growth-stage companies that want stability over speed, but if you need fast decisions or aggressive growth strategies, look elsewhere. Their Quebec focus means they really understand the Canadian market, which is gold if that's your target.

Centana is a solid, no-drama growth equity shop that does exactly what it says on the tin. The partners are experienced operators who actually understand SaaS metrics and won't waste your time with fluff. They're particularly strong at helping companies navigate the tricky $10-50M revenue stage where growth starts getting harder. The downside? They're not going to lead your Series A or take big swings on unproven markets. If you need patient capital and operational expertise for scaling proven business models, they're worth the conversation.

Chrysalis is the definition of a solid, no-drama regional fund that actually knows how to build businesses. They're not chasing unicorns or AI buzzwords - they want profitable, growing B2B software companies and they'll roll up their sleeves to help you get there. Bob Lowe genuinely knows operations and isn't afraid to challenge founders on their metrics. The downside? They're not going to lead your $50M Series C, and if you're building something that needs massive scale or network effects, they might not get it. But if you want smart money that won't micromanage and can actually help with enterprise sales strategy, they're underrated.

Here's the thing - Coliseum isn't really a VC fund, they're a hedge fund that sometimes writes private checks. If you're a seed or Series A startup, you're barking up the wrong tree. They're value investors who look for established businesses with clear paths to profitability or companies in distressed situations where they can drive operational changes. Think of them more like a growth equity shop that occasionally does private deals. They're not going to give you the typical VC support ecosystem, board guidance, or network effects. If you need actual venture capital, keep looking.

Concord is a solid, if unremarkable, healthcare-focused fund that knows their lane and stays in it. They're genuine healthcare operators who understand the space's complexities, but don't expect flashy marketing or Silicon Valley-style growth hacking. Their Nashville base gives them strong regional deal flow and they're particularly good at healthcare services plays. Partners are approachable and founder-friendly, though decision-making can be slower than coastal funds. They're better at picking solid, cash-flow positive businesses than swinging for unicorn home runs.